Anna Bagnato

List of Publications by Year
in descending order

112 papers	5,786 citations	61984 43 h-index	76900 74 g-index
112 all docs	112 docs citations	112 times ranked	4855 citing authors

#	Article	IF	Citations
1	Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 157.	8.6	5
2	YAP and endothelin-1 signaling: an emerging alliance in cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 27.	8.6	23
3	Endothelin-1 drives invadopodia and interaction with mesothelial cells through ILK. Cell Reports, 2021, 34, 108800.	6.4	15
4	Ovarian Cancer-Driven Mesothelial-to-Mesenchymal Transition is Triggered by the Endothelin-1/Î²-arr1 Axis. Frontiers in Cell and Developmental Biology, 2021, 9, 764375.	3.7	4
5	Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer. Communications Biology, 2020, 3, 677.	4.4	13
6	Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. Cancer Letters, 2020, 492, 84-95.	7.2	12
7	Tumor Cellular and Microenvironmental Cues Controlling Invadopodia Formation. Frontiers in Cell and Developmental Biology, 2020, 8, 584181.	3.7	35
8	Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma. Frontiers in Oncology, 2020, 10, 600025.	2.8	9
9	In reply to SchÃfer etÂal: new evidence on the role of endothelinâ€1 axis as a potential therapeutic target in multiple myeloma. British Journal of Haematology, 2019, 184, 1052-1055.	2.5	9
10	Î²-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. Nature Communications, 2019, 10, 3196.	12.8	40
11	Targeting Endothelin-1 Receptor/Î²-Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach. Frontiers in Endocrinology, 2019, 10, 609.	3.5	19
12	New insights into the regulation of the actin cytoskeleton dynamics by GPCR/Î²-arrestin in cancer invasion and metastasis. International Review of Cell and Molecular Biology, 2019, 346, 129-155.	3.2	16
13	Methods to Investigate Î²-Arrestin-1/Î²-Catenin Signaling in Ovarian Cancer Cells. Methods in Molecular Biology, 2019, 1957, 393-406.	0.9	2
14	New Routes in GPCR/Î²-Arrestin-Driven Signaling in Cancer Progression and Metastasis. Frontiers in Pharmacology, 2019, 10, 114.	3.5	38
15	Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer. Matrix Biology, 2019, 81, 17-33.	3.6	23
16	hMENA is a key regulator in endothelin-1/Î²-arrestin1â€“induced invadopodial function and metastatic process. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3132-3137.	7.1	21
17	Endothelin-1 receptor drives invadopodia: Exploiting how Î²-arrestin-1 guides the way. Small GTPases, 2018, 9, 394-398.	1.6	12
18	Endothelinâ€1 receptor blockade as new possible therapeutic approach in multiple myeloma. British Journal of Haematology, 2017, 178, 781-793.	2.5	21

#	Article	IF	Citations
19	Blocking endothelin-1-receptor/Î²-catenin circuit sensitizes to chemotherapy in colorectal cancer. Cell Death and Differentiation, 2017, 24, 1811-1820.	11.2	34
20	Targeting endothelin-1 receptor/Î²-arrestin1 network for the treatment of ovarian cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 925-932.	3.4	9
21	Î²-arrestin1 at the cross-road of endothelin-1 signaling in cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 121.	8.6	47
22	Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis. Life Sciences, 2016, 159, 43-48.	4.3	25
23	Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer. Life Sciences, 2016, 159, 49-54.	4.3	13
24	Endothelin therapeutics in cancer: Where are we?. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R469-R475.	1.8	38
25	Endothelin A receptor drives invadopodia function and cell motility through the Î²-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. Oncogene, 2016, 35, 3432-3442.	5.9	53
26	miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget, 2016, 7, 4009-4023.	1.8	49
27	Nuclear Î²-arrestin1 is a critical cofactor of hypoxia-inducible factor-1Î± signaling in endothelin-1-induced ovarian tumor progression. Oncotarget, 2016, 7, 17790-17804.	1.8	33
28	Disrupting the endothelin and Wnt relationship to overcome chemoresistance. Molecular and Cellular Oncology, 2015, 2, e995025.	0.7	3
29	Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. Nucleic Acids Research, 2014, 42, 2945-2957.	14.5	45
30	Inhibition of Tumor Growth and Angiogenesis by SP-2, an Antiâ€“Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody. Molecular Cancer Therapeutics, 2014, 13, 916-925.	4.1	21
31	Endothelin A Receptor/Î²-Arrestin Signaling to the Wnt Pathway Renders Ovarian Cancer Cells Resistant to Chemotherapy. Cancer Research, 2014, 74, 7453-7464.	0.9	89
32	Endothelin-1 regulates hypoxia-inducible factor-1Î± and -2Î± stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells. Life Sciences, 2014, 118, 185-190.	4.3	19
33	Î²-Arrestin-1 Drives Endothelin-1â€“Mediated Podocyte Activation and Sustains Renal Injury. Journal of the American Society of Nephrology: JASN, 2014, 25, 523-533.	6.1	63
34	The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis, 2014, 35, 840-848.	2.8	44
35	Î²-Arrestin 1 is required for endothelin-1-induced NF-ÎºB activation in ovarian cancer cells. Life Sciences, 2014, 118, 179-184.	4.3	64
36	Abstract 2684: Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody. , 2014, , .		0

#	Article	IF	Citations
37	Abstract 3144: PDZ-RhoGEF/Î²-arrestin-1 interaction mediates endothelin A receptor-induced RhoA activation and cell motility in ovarian tumor cells. , 2014, , .		0
38	Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nature Reviews Cancer, 2013, 13, 637-651.	28.4	282
39	LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. Journal of Molecular Medicine, 2013, 91, 83-94.	3.9	63
40	A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). Gynecologic Oncology, 2013, 130, 31-37.	1.4	20
41	Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. Journal of Molecular Medicine, 2013, 91, 395-405.	3.9	48
42	Î²-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced Î²-catenin signaling. Oncogene, 2013, 32, 5066-5077.	5.9	79
43	Understanding and Overcoming Chemoresistance in Ovarian Cancer: Emerging Role of the Endothelin Axis. Current Oncology, 2012, 19, 36-38.	2.2	25
44	The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future. Current Pharmaceutical Design, 2012, 18, 2720-2733.	1.9	7
45	The endothelin A receptor and epidermal growth factor receptor signaling converge on Î²-catenin to promote ovarian cancer metastasis. Life Sciences, 2012, 91, 550-556.	4.3	11
46	Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells. Life Sciences, 2012, 91, 638-643.	4.3	15
47	Abstract 493: Endothelin-1 induces activation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. , 2012, , .		0
48	Abstract 3086: Î±-arrestin-1 acts as a nuclear transcriptional regulator of endothelin A receptor signalling to promote ovarian cancer progression. , 2012, , .		0
49	Role of the endothelin axis and its antagonists in the treatment of cancer. British Journal of Pharmacology, 2011, 163, 220-233.	5.4	103
50	Lost in translation: bridging the gap between cancer research and effective therapies. Cell Death and Differentiation, 2011, 18, 1082-1084.	11.2	1
51	Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells. Clinical Cancer Research, 2011, 17, 2350-2360.	7.0	167
52	Abstract 698: Î²-arrestin-1 as nuclear signalling element essential for endothelin A receptor-induced epithelial to mesenchymal transition and chemoresistance. , 2011, , .		0
53	Abstract 707: Acquisition of chemoresistance and epithelial to mesenchymal phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. , 2011, , .		0
54	Abstract 3473: Endothelin axis autocrine loop is positively regulated by the interplay between ET-1 and hypoxia-inducible factor-1Î± in melanoma cells. , 2011, , .		0

#	Article	IF	Citations
55	The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R395-R404.	1.8	25
56	Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancerThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. Canadian Journal of Physiology and Pharmacology, 2010, 88, 676-681.	1.4	8
57	Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cellsThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. Canadian Journal of Physiology and Pharmacology, 2010, 88, 782-787.	1.4	19
58	Î²-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinaseThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. Canadian Journal of Physiology and Pharmacology, 2010, 88, 796-801.	1.4	28
59	Endothelin-1 Inhibits Prolyl Hydroxylase Domain 2 to Activate Hypoxia-Inducible Factor-1Î± in Melanoma Cells. PLoS ONE, 2010, 5, e11241.	2.5	50
60	Convergent pathways link the endothelin A receptor to the Î²-catenin: The Î²-arrestin connection. Cell Cycle, 2009, 8, 1461-1465.	2.6	11
61	Î²-Arrestin links endothelin A receptor to Î²-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2806-2811.	7.1	159
62	Endothelin-1 Stimulates Lymphatic Endothelial Cells and Lymphatic Vessels to Grow and Invade. Cancer Research, 2009, 69, 2669-2676.	0.9	87
63	Convergent pathways link the endothelin A receptor to the beta-catenin: the beta-arrestin connection. Cell Cycle, 2009, 8, 1462-3.	2.6	5
64	The endothelin axis in cancer. International Journal of Biochemistry and Cell Biology, 2008, 40, 1443-1451.	2.8	172
65	The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.. Canadian Journal of Physiology and Pharmacology, 2008, 86, 473-484.	1.4	78
66	Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity. Cancer Research, 2007, 67, 6351-6359.	0.9	65
67	Endothelin-1 and Endothelin-3 Promote Invasive Behavior via Hypoxia-Inducible Factor-1Î± in Human Melanoma Cells. Cancer Research, 2007, 67, 1725-1734.	0.9	84
68	ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Molecular Cancer Therapeutics, 2007, 6, 2003-2011.	4.1	61
69	Epithelial-Mesenchymal Transition in Ovarian Cancer Progression: A Crucial Role for the Endothelin Axis. Cells Tissues Organs, 2007, 185, 85-94.	2.3	63
70	Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Molecular Cancer Therapeutics, 2006, 5, 1483-1492.	4.1	73
71	Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Molecular Cancer Therapeutics, 2006, 5, 833-842.	4.1	74
72	Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. Experimental Biology and Medicine, 2006, 231, 1123-7.	2.4	10

#	Article	IF	Citations
73	Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Experimental Biology and Medicine, 2006, 231, 1128-31.	2.4	18
74	ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Experimental Biology and Medicine, 2006, 231, 1132-5.	2.4	7
75	Emerging role of the endothelin axis in ovarian tumor progression. Endocrine-Related Cancer, 2005, 12, 761-772.	3.1	80
76	Endothelin-1 Promotes Epithelial-to-Mesenchymal Transition in Human Ovarian Cancer Cells. Cancer Research, 2005, 65, 11649-11657.	0.9	161
77	Targeting Endothelin Axis in Cancer. , 2004, 119, 293-314.		17
78	Endothelin B Receptor Blockade Inhibits Dynamics of Cell Interactions and Communications in Melanoma Cell Progression. Cancer Research, 2004, 64, 1436-1443.	0.9	115
79	Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells. Clinical Cancer Research, 2004, 10, 4670-4679.	7.0	62
80	Therapeutic Targeting of the Endothelin-A Receptor in Human Ovarian Carcinoma: Efficacy of Cytotoxic Agents is Markedly Enhanced by Co-administration with Atrasentan. Journal of Cardiovascular Pharmacology, 2004, 44, S132-S135.	1.9	7
81	Endothelin-1-induced Prostaglandin E2-EP2, EP4 Signaling Regulates Vascular Endothelial Growth Factor Production and Ovarian Carcinoma Cell Invasion. Journal of Biological Chemistry, 2004, 279, 46700-46705.	3.4	91
82	Endothelin receptors as novel targets in tumor therapy. Journal of Translational Medicine, 2004, 2, 16.	4.4	96
83	Endothelin-1 Stimulates Cyclooxygenase-2 Expression in Ovarian Cancer Cells Through Multiple Signaling Pathways: Evidence for Involvement of Transactivation of the Epidermal Growth Factor Receptor. Journal of Cardiovascular Pharmacology, 2004, 44, S140-S143.	1.9	20
84	Endothelin-B Receptor Blockade Inhibits Molecular Effectors of Melanoma Cell Progression. Journal of Cardiovascular Pharmacology, 2004, 44, S136-S139.	1.9	12
85	Targeting Endothelin Receptor Type A in Human Cervical Carcinoma Cells. Journal of Cardiovascular Pharmacology, 2004, 44, S72-S75.	1.9	5
86	The endothelin axis: emerging role in cancer. Nature Reviews Cancer, 2003, 3, 110-116.	28.4	527
87	Endothelin Receptor Blockade Inhibits Molecular Effectors of Kaposi's Sarcoma Cell Invasion and Tumor Growth in Vivo. American Journal of Pathology, 2003, 163, 753-762.	3.8	55
88	Emerging role of endothelin-1 in tumor angiogenesis. Trends in Endocrinology and Metabolism, 2003, 14, 44-50.	7.1	123
89	Endothelin-1 Decreases Gap Junctional Intercellular Communication by Inducing Phosphorylation of Connexin 43 in Human Ovarian Carcinoma Cells. Journal of Biological Chemistry, 2003, 278, 41294-41301.	3.4	64
90	Therapies for cancer targeting endothelin receptors. Drugs of the Future, 2003, 28, 983.	0.1	0

#	Article	IF	Citations
91	Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Research, 2003, 63, 2447-53.	0.9	90
92	Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1Î± in Ovarian Carcinoma Cells. Journal of Biological Chemistry, 2002, 277, 27850-27855.	3.4	182
93	Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. Molecular Pharmacology, 2002, 61, 524-532.	2.3	132
94	Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clinical Science, 2002, 103, 302S-305S.	4.3	24
95	Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clinical Science, 2002, 103, 306S-309S.	4.3	31
96	Endothelin receptor blockade inhibits the growth of human papillomavirus-associated cervical carcinoma. Clinical Science, 2002, 103, 310S-313S.	4.3	9
97	ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clinical Science, 2002, 103, 318S-321S.	4.3	21
98	Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Research, 2002, 62, 6381-4.	0.9	67
99	Endothelin Receptor Blockade Inhibits Proliferation of Kaposiâ€™s Sarcoma Cells. American Journal of Pathology, 2001, 158, 841-847.	3.8	34
100	Expression of endothelin 1 and endothelin A receptor in HPVâ€associated cervical carcinoma: new potential targets for anticancer therapy. FASEB Journal, 2000, 14, 2277-2283.	0.5	57
101	Role of Endothelin-1 in Neovascularization of Ovarian Carcinoma. American Journal of Pathology, 2000, 157, 1537-1547.	3.8	184
102	Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. American Journal of Pathology, 2000, 157, 1703-1711.	3.8	322
103	The E5 Oncoprotein of Human Papillomavirus Type 16 Enhances Endothelin-1-Induced Keratinocyte Growth. Virology, 1998, 248, 1-5.	2.4	41
104	Endothelins as Autocrine Regulators of Tumor Cell Growth. Trends in Endocrinology and Metabolism, 1998, 9, 378-383.	7.1	74
105	The autonomous growth of human papillomavirus type 16-immortalized keratinocytes is related to the endothelin-1 autocrine loop. Journal of Virology, 1997, 71, 6898-6904.	3.4	12
106	Identification of the ETA Receptor Subtype That Mediates Endothelin-Induced Autocrine Proliferation of Normal Human Keratinocytes. Biochemical and Biophysical Research Communications, 1995, 209, 80-86.	2.1	29
107	Expression of the growth hormone-releasing hormone gene and its peptide product in the rat ovary. Endocrinology, 1992, 130, 1097-1102.	2.8	65
108	Gonadotropin-Induced Expression of Receptors for Growth Hormone Releasing Factor in Cultured Granulosa Cells*. Endocrinology, 1991, 128, 2889-2894.	2.8	32

#	Article	IF	Citations
109	Modulation of adriamycin uptake by lonidamine in ehrlich ascites tumor cells. Experimental and Molecular Pathology, 1988, 49, 421-431.	2.1	19
110	Lonidamine-Induced Membrane Permeability and the Effect of Adriamycin on the Energy Metabolism of Ehrlich Ascites Tumor Cells. Annals of the New York Academy of Sciences, 1988, 551, 270-272.	3.8	0
111	Effect of adriamycin on electron transport in rat heart, liver, and tumor mitochondria. Experimental and Molecular Pathology, 1987, 46, 123-135.	2.1	39
112	Effect of hyperthermia on electron transport in ehrlich ascites tumor mitochondria. Experimental and Molecular Pathology, 1987, 46, 279-293.	2.1	3